Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the Italian network on secondary leukemias
Open Access
- 4 February 2015
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 90 (5), E80-E85
- https://doi.org/10.1002/ajh.23966
Abstract
Therapy‐related myeloid neoplasms (t‐MN) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. We report data on 277 t‐MN patients, recruited between 1999 and 2013 by the Italian Network on Secondary Leukemias (104 retrospectively and 173 prospectively registered). Median age at t‐MN diagnosis was 64 years (range, 21–87). Most frequent primary malignancies (PMs) were lymphoproliferative diseases and breast cancer. One hundred and thirty‐three patients had received chemotherapy (CHT), 43 patients radiotherapy (RT), and 101 patients combined CHT/RT for PM. Median time between cytotoxic treatment and t‐MN was 5.7 years, with t‐MN following RT alone associated with significantly longer latency, compared to CHT or combined CHT/RT (mean, 11.2 vs. 7.1 years, P = 0.0005). The addition of topoisomerase‐II inhibitors to alkylating agents was associated with shorter latency compared to alkylating agents alone (median, 6 vs. 8.4 years, P = 0.02). Median survival was 14.6 months from t‐MN diagnosis, and was significantly longer in patients treated with allogeneic stem cell transplantation. Significant factors for survival at the multivariable analysis included age, adverse karyotype, and degree of anemia. Our data underline the prognostic importance of karyotype and age in t‐MN, similar to de novo acute myeloid leukemia. Treatment approaches should not preclude the use of conventional treatments for younger t‐MN patients, including allogeneic stem cell transplantation as potentially curative approach. Am. J. Hematol. 90:E80–E85, 2015.This publication has 27 references indexed in Scilit:
- Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemiaHaematologica, 2013
- Outcome of therapy-related myeloid neoplasms treated with azacitidineJournal of Hematology & Oncology, 2012
- THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPYMediterranean Journal of Hematology and Infectious Diseases, 2012
- The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AMLBlood, 2011
- PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASMMediterranean Journal of Hematology and Infectious Diseases, 2011
- Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityBlood, 2009
- Genome-wide association study identifies novel breast cancer susceptibility lociNature, 2007
- Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trialsAnnals of Oncology, 2005
- Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of KaryotypeJournal of Clinical Oncology, 2004
- Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesBlood, 2003